<DOC>
	<DOC>NCT02075073</DOC>
	<brief_summary>The purpose of this study is to compare the pharmacokinetics, safety, tolerability and immunogenicity of SB3 and Herceptin® (EU sourced Herceptin® and US sourced Herceptin®) in healthy male subjects.</brief_summary>
	<brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Healthy male subjects Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and 29.9 kg/m², inclusive. history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus), psychiatric or significant allergic disease excluding mild asymptomatic allergies. history of and/or current cardiac disease previously received any monoclonal antibody or fusion protein. history of cancer including lymphoma, leukaemia and skin cancer. Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) between Screening and the End of Study visit. intake medication with a halflife &gt; 24 h within 1 month or 10 halflives of the medication prior to the administration of investigational product.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>